August 14, 2020
Vicore Pharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE...
Read more
Read more
August 12, 2020
Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2020 results, Thursday 20 August
Oslo, Norway, 12 August 2020 – Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2020 results on Thursday 20 August 2020. An online presentat...
Read more
Read more
August 11, 2020
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results And Business Update
- Following Fusion's June 2020 initial public offering, cash runway extended into 2024
HAMILTON, ON and BOSTON, Aug. 11, 2020 /PRNewswire/ -- Fusion Pharmace...
Read more
Read more
August 11, 2020
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeut...
Read more
Read more
August 10, 2020
Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US
Uppsala, Sweden – August 10, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces it has received a “paragraph IV” patent certification notice from Sun Phar...
Read more
Read more
August 10, 2020
Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer
Oslo, Norway, 10 August 2020
Nordic Nanovector ASA (OSE: NANO) announces that Dr Christine Wilkinson Blanc has been appointed Chief Medical Officer with immediate effe...
Read more
Read more
August 7, 2020
Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study
STOCKHOLM — August 7, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain...
Read more
Read more
August 6, 2020
Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL
Oslo, Norway, 6 August 2020
Nordic Nanovector ASA (OSE: NANO) today announces that, following a planned interim analysis of the PARADIGME Phase 2b pivotal trial of Be...
Read more
Read more
August 5, 2020
Fusion Pharmaceuticals To Present At The 2020 Wedbush PacGrow Healthcare Virtual Conference
HAMILTON, Ontario and BOSTON, Aug. 5, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generati...
Read more
Read more
August 4, 2020
Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
STOCKHOLM — August 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study,...
Read more
Read more